Department of Defense explores AI-enabled infection control

The technology examines vital signs and other biomarkers to predict the likelihood of infection


The technology, developed in part by the U.S. Department of Defense (DoD), examines vital signs and other biomarkers to predict the likelihood of infection up to 48 hours ahead of clinical suspicion, according to an article on the Healthcare IT News website.

The technology is intended for U.S. service members but expected to be used widely by civilians. 

The healthcare technology company, Royal Philips, and the DoD collaborated on the 18-month project.

The technology is expected to be broadly applicable to civilian healthcare settings. It will eventually be used in scenarios where vital signs and biomarkers fluctuate, like during physical exertion and heat stress.

Read the article.



October 29, 2019


Topic Area: Infection Control


Recent Posts

Healthcare Is the New Retail

How site selection strategies are shaping the future of medical real estate.


Bridgeway Behavioral Health Services Launches Campaign to Renovate Health Center

The $2 million capital campaign aims to renovate and expand the outpatient behavioral health center in Elizabeth, New Jersey.


Ground Broken for New North Dakota State Hospital

The 300,000-square-foot facility in Jamestown will provide 140 beds in a modern, trauma-informed care environment.


AI Usage for Healthcare Facilities

People in all industries are finding more use cases for artificial intelligence.


Ground Broken on Pelican Valley Senior Living Modernization Project

It is expected to reach completion in early-mid 2027.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.